Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal

Total Page:16

File Type:pdf, Size:1020Kb

Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site. Mutations targeting each po- sociated factor (TRAF). In particular, LTβR signals via TRAF3 tential receptor-binding site in an engineered single-chain variant and the structure of a peptide derived from the intracellular region α β fi κ of LT 1 2 reveal the high-af nity site. NF- B reporter assays fur- of LTβR bound to the TRAF3 C-terminal domain revealed a 3:3 ther validate that disruption of receptor interactions at either site trimeric complex (12, 13). is sufficient to prevent signaling via LTβR. Most TNFSF ligands are compact homotrimers formed by IMMUNOLOGY protomers possessing a conserved beta-strand jellyroll fold. Each crystallography | cytokines | mechanism | biophysics protomer is formed by an inner and outer β-sheet consisting of strands A’AHCF and B’BGDE, respectively (14). In contrast, he TNF receptor and ligand superfamilies (TNFRSF and multidomain TNFRSFs have an elongated shape and are com- TTNFSF, respectively) play critical roles in mammalian bi- posed of pseudorepeats of ∼40 residue cysteine-rich domains ology and mediate proinflammatory immune responses. Lym- (CRDs). The extracellular domain (ECD) of LTβR comprises α β photoxin (LT)- and LT are two related TNFSF members four CRDs and is expected to have similar overall architecture to produced predominately by activated cells of the innate and other multidomain TNFRSF members such as TNFR1. Crystal α adaptive immune response. LT exists as a secreted homotri- structures of several ligand–receptor complexes in this super- α meric molecule (LT 3) that signals via TNFR1 and TNFR2, or family (15–23) revealed that receptors bind in a symmetrical as a heterotrimer with LTβ on the cell surface (major form LTα β , minor form LTα β ) and signals through the LTβ re- 1 2 2 1 Significance ceptor (LTβR) (1). As a heterotrimer rather than a homotrimer, LTα1β2 is unique in the TNFSF. The role of LT in the immune response has been well charac- Cytokines are proteins that modulate the activity of target cells terized as critical for the development and orchestration of robust via activation of cell-surface receptors. The trimeric cytokines immune responses (2). Signaling through LTβR, expressed on of the tumor necrosis factor superfamily typically signal by nonhematopoeitic cells and follicular dendritic cells, directs normal inducing homotrimerization of their cognate receptors. We use development of lymph nodes and appropriate germinal center ar- structural and biophysical approaches to show that the unique heterotrimeric tumor necrosis factor superfamily member Lym- chitecture via the elaboration of various cytokines and chemokines, α β as revealed in LTα-, LTβ-, or LTβR-deficient mice (3, 4). During photoxin (LT) 1 2 induces dimerization rather than trimerization fi of the LTβ Receptor (LTβR). Cellular signaling assays were used chronic immune responses, cellular effectors can in ltrate target β fi tissue and organize anatomically into de novo lymphoid structures, to show that dimerization of LT Rissuf cient to activate in- instigated and maintained by LT-mediated pathways (5). tracellular signaling processes. Furthermore, disruption of re- ceptor interactions at either site prevents signaling via LTβR, Surface LTα1β2 is detected on subsets of activated T and B cells and NK cells (6–9). Dysregulation of these immune cell challenging the existing paradigm that trimeric complexes are types underlies the pathogenesis of autoimmune diseases. In required for signal transduction by the TNF family cytokines. mouse models of rheumatoid arthritis (RA), experimental au- Author contributions: J.S., J.Y., E.Y.C., M.A.S., J.L.G., and S.G.H. designed research; J.S., toimmune encephalomyelitis (EAE), and delayed-type hyper- J.Y., E.Y.C., and S.G.H. performed research; J.S., E.Y.C., M.A.S., J.L.G., and S.G.H. analyzed sensitivity (DTH), treatment with a depleting antibody specificto data; and J.S., J.Y., E.Y.C., J.L.G., and S.G.H. wrote the paper. murine LTα resulted in amelioration of disease in all circum- Conflict of interest statement: All authors are employees of Genentech, Inc. fi stances. In these studies, the Fc-dependent ef cacy achieved with This article is a PNAS Direct Submission. α anti-LT resulted from depletion of pathogenic LT-expressing Freely available online through the PNAS open access option. β Th1 and Th17 cells. Moreover, blockade of LT R signaling using Data deposition: The atomic coordinates and structure factors have been deposited in the a decoy receptor fusion protein, LTβR-Ig, was sufficient to drive Protein Data Bank, www.pdb.org (PDB ID codes 4MXV and 4MXW). fi ef cacy in a number of autoimmune models when delivered 1J.S. and J.Y. contributed equally to this work. α preventatively (10). Motivated by the concerted effects of LT and 2To whom correspondence may be addressed. E-mail: [email protected] or grogan. LTβ in driving major inflammatory pathways and pathologies, we [email protected]. α previously generated a humanized anti-LT mAb (MLTA3698A, This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. hereafter referred to as anti-LTα), and demonstrated increased 1073/pnas.1310838110/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1310838110 PNAS Early Edition | 1of6 Downloaded by guest on October 1, 2021 manner at the monomer–monomer interfaces of the ligands, This complex retains the threefold symmetry of the LTα3 trimer. with CRD2 and CRD3 mediating most receptor–ligand inter- Each LTα protomer binds one copy of anti-LTα Fab (Fig. 1D). actions (Fig. S1A). Strands A’,B’, and B and the DE-loop and the FG-loop on the Unlike most TNFSF ligands, biochemical studies surprisingly outer surface of the monomer comprise the majority of the anti- indicated that the LIGHT [TNFSF member homologous to LT, LTα epitope (Fig. 1E). This binding mode differs from that seen in inducible expression, competes with herpes simplex virus (HSV) a structure of CD40L bound to the fab fragment of a blocking glycoprotein D for HSV entry mediator (HVEM), a receptor antibody (24) in which the antibody directly competes for the re- expressed on T lymphocytes; TNFSF14] homotrimer and the ceptor-binding site. Like anti-LTα, the Fab fragment of infliximab LTα1β2 heterotrimer are only capable of binding two copies of with TNF (25) also binds to the outer surface of a single monomer their cognate receptor, LTβR. However, difficulty in making of TNF. However, the infliximab–TNF interaction centers on the recombinant, soluble LTα1β2 precluded further characterization EF loop in the tip of the trimer, whereas anti-LTα Fab binds to the (1). Nonetheless, the inherent asymmetry of the LTα1β2 hetero- wide part of the trimer. trimer suggests three distinct possible receptor-binding sites in Overlay of the LTα3–(anti–LTα-Fab)3 and the LTα3–TNFR13 LTα1β2 as opposed to three equivalent sites in a homotrimer (Fig. structures unexpectedly revealed minimal overlap between the S1 B and C). Herein we draw on structural, biochemical, and TNFR1 epitope and the anti-LTα epitope (Fig. S1 D and E). cellular data to show that dimeric clustering of LTβRbythe However, the Fab occupies part of the same 3D space as would LTα1β2 heterotrimer triggers signal transduction and that dis- be occupied by receptor during a signaling event, suggesting that rupting one receptor-binding site on LTα1β2 is sufficient to block steric hindrance contributes to the ability of anti-LTα to compete signaling through LTβR. with TNFR1 or TNFR2 for ligand. Anti-LTα binding also changes the conformation of the LTα DE and the AA’ loops, which con- Results tain the critical residues Y142 and D84, which are essential for Anti-LTα Binds to LTα at a Different Site from TNFR1 and Blocks receptor binding and cytotoxic activity of LTα (26). This confor- Signaling by Both TNFR1 and LTβR. To assess the binding of anti- mational change is an allosteric effect, as anti-LTα does not directly α α α β LT toward LT 3 and LT 1 2, we stimulated HeLa cells stably contact these residues.
Recommended publications
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • LIGHT Is Expressed in Foam Cells and Involved in Destabilization of Atherosclerotic Plaques Through Induction of Matrix Metalloproteinase-9 and IL-8
    LIGHT is Expressed in Foam Cells and Involved in Destabilization of Atherosclerotic Plaques through Induction of Matrix Metalloproteinase-9 and IL-8 Won-Jung Kim and Won-Ha Lee Department of Genetic Engineering, Kyungpook National University, Daegu, Korea ABSTRACT Background: LIGHT (TNFSF14) is a member of tumor necrosis factor superfamily and is the ligand for TR2 (TNFRSF14/HVEM). LIGHT is known to have pro- inflammatory roles in atherosclerosis. Methods: To find out the expression pattern of LIGHT in atherosclerotic plaques, immunohistochemical analysis was performed on human carotid atherosclerotic plaque specimens. LIGHT induced atherogenic events using human monocytic cell line THP-1 were also investigated. Results: Imm- unohistochemical analysis revealed expression of LIGHT and TR2 in foam cell rich regions in the atherosclerotic plaques. Double immunohistochemical analysis further confirmed the expression of LIGHT in foam cells. Stimulation of THP-1 cells, which express TR2, with either recombinant LIGHT or immobilized anti-TR2 monoclonal antibody induced interleukin-8 and matrix metalloproteinase(MMP)-9. Electrophoretic mobility shift assay demonstrated that LIGHT induces nuclear localization of tran- scription factor, nuclear factor (NF)-κB. LIGHT induced activation of MMP-9 is mediated by NF-κB, since treatment of THP-1 cells with the NF-κB inhibitor PDTC (pyrrolidine dithiocarbamate) completely blocked the activation of MMP-9. Conclusion: These data indicate that LIGHT is expressed in foam cells in atherosclerotic plaques and is involved in atherogenesis through activation of pro-atherogenic cytokine IL-8 and destabilization of plaque by inducing matrix degrading enzyme. (Immune Network 2004;4(2):116-122) Key Words: Atherosclerosis, inflammation, matrix metalloproteinase, LIGHT, TNFSF inflammatory cytokines and matrix metallopro- Introduction teinases, and expression of adhesion molecules and Members of tumor necrosis factor superfamily tissue factor (7,8).
    [Show full text]
  • Death of HT29 Adenocarcinoma Cells Induced by TNF Family Receptor Activation Is Caspase-Independent and Displays Features of Both Apoptosis and Necrosis
    Cell Death and Differentiation (2002) 9, 1321 ± 1333 ã 2002 Nature Publishing Group All rights reserved 1350-9047/02 $25.00 www.nature.com/cdd Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis 1 ,1 CA Wilson and JL Browning* Introduction 1 Department of Exploratory Biology, Biogen, 12 Cambridge Center, Cambridge, Receptors in the TNF family can initiate both canonical MA 02142, USA apoptotic and necrotic death events.1 Prototypical apoptosis * Corresponding author: JL Browning, Department of Exploratory Biology, follows activation of the Fas receptor on T cells leading to Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA; caspase activation and a cascade of events eventually Tel: 617 679-3312; Fax: 617 679-2304; E-mail: [email protected] culminating in the various hallmarks of apoptosis.2,3 Yet even Received 7.12.01; revised 26.1.02; accepted 22.7.02 in this familiar case, Fas/FADD can trigger necrosis in T cells 4,5 Edited by B Osborne in the absence of caspase signaling. In the well-studied L929 fibroblast line, Fas activation triggers apoptosis while TNF initiates a necrotic event that is actually enhanced by Abstract caspase inhibition.1 Similarly, TNF signaling in the presence of caspase inhibitors was reported to lead to the necrosis of The HT29 adenocarcinoma is a common model of epithelial NIH3T3 fibroblasts and the myeloid U937 cell line.6 It has cell differentiation and colorectal cancer and its death is an oft- been dogmatic that apoptosis is only initiated by those TNF analyzed response to TNF family receptor signaling.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • OSCAR Is a Receptor for Surfactant Protein D That Activates TNF- Α Release from Human CCR2 + Inflammatory Monocytes
    OSCAR Is a Receptor for Surfactant Protein D That Activates TNF- α Release from Human CCR2 + Inflammatory Monocytes This information is current as Alexander D. Barrow, Yaseelan Palarasah, Mattia Bugatti, of September 25, 2021. Alex S. Holehouse, Derek E. Byers, Michael J. Holtzman, William Vermi, Karsten Skjødt, Erika Crouch and Marco Colonna J Immunol 2015; 194:3317-3326; Prepublished online 25 February 2015; Downloaded from doi: 10.4049/jimmunol.1402289 http://www.jimmunol.org/content/194/7/3317 Supplementary http://www.jimmunol.org/content/suppl/2015/02/24/jimmunol.140228 http://www.jimmunol.org/ Material 9.DCSupplemental References This article cites 40 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/194/7/3317.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology OSCAR Is a Receptor for Surfactant Protein D That Activates TNF-a Release from Human CCR2+ Inflammatory Monocytes Alexander D.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma
    diagnostics Article Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma Franziska Werner 1 , Christine Wagner 1, Martin Simon 1, Katharina Glatz 2, Kirsten D. Mertz 3,4 , Heinz Läubli 5 , Erika Richtig 6, Johannes Griss 7 and Stephan N. Wagner 1,* 1 Laboratory of Molecular Dermato-Oncology and Tumor Immunology, Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (F.W.); [email protected] (C.W.); [email protected] (M.S.) 2 Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland; [email protected] 3 Institute of Pathology, Cantonal Hospital Baselland, 4410 Liestal, Switzerland; [email protected] 4 University of Basel, 4001 Basel, Switzerland 5 Laboratory for Cancer Immunotherapy, Department of Biomedicine and Medical Oncology, Department of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland; [email protected] 6 Department of Dermatology, Medical University of Graz, 8036 Graz, Austria; [email protected] 7 Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected] Abstract: Activated antigen-experienced B cells play an unexpected complex role in anti-tumor immunity in human melanoma patients. However, correlative studies between B cell infiltration and Citation: Werner, F.; Wagner, C.; tumor progression are limited by the lack of distinction between functional B cell subtypes. In this Simon, M.; Glatz, K.; Mertz, K.D.; study, we examined a series of 59 primary and metastatic human cutaneous melanoma specimens Läubli, H.; Richtig, E.; Griss, J.; with B cell infiltration.
    [Show full text]
  • Targeting the Lymphotoxin-B Receptor with Agonist Antibodies As a Potential Cancer Therapy
    Research Article Targeting the Lymphotoxin-B Receptor with Agonist Antibodies as a Potential Cancer Therapy Matvey Lukashev,1 Doreen LePage,1 Cheryl Wilson,1 Ve´ronique Bailly,1 Ellen Garber,1 AlexLukashin, 1 Apinya Ngam-ek,1 Weike Zeng,1 Norman Allaire,1 Steve Perrin,1 Xianghong Xu,1 Kendall Szeliga,1 Kathleen Wortham,1 Rebecca Kelly,1 Cindy Bottiglio,1 Jane Ding,1 Linda Griffith,1 Glenna Heaney,1 Erika Silverio,1 William Yang,1 Matt Jarpe,1 Stephen Fawell,1 Mitchell Reff,1 Amie Carmillo,1 Konrad Miatkowski,1 Joseph Amatucci,1 Thomas Crowell,1 Holly Prentice,1 Werner Meier, 1 Shelia M. Violette,1 Fabienne Mackay,1 Dajun Yang,2 Robert Hoffman,3 and Jeffrey L. Browning1 1Departments of Immunobiology, Oncopharmacology, Molecular Engineering, Molecular Profiling, Molecular Discovery, Antibody Humanization, and Cellular Engineering, Biogen Idec, Cambridge, Massachusetts; 2Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan; and 3AntiCancer, Inc., San Diego, California Abstract receptor (TRAILR) 1/2, death receptor (DR) 3, DR6, and possibly ectodermal dysplasia receptor (EDAR). These TNFRs harbor The lymphotoxin-B receptor (LTBR) is a tumor necrosis factor signaling adaptor motifs termed death domains that can initiate receptor family member critical for the development and the extrinsic apoptosis program. In addition, TNFRs of this group maintenance of various lymphoid microenvironments. Herein, can exert antitumor effects via other mechanisms that include we show that agonistic anti-LTBR monoclonal antibody (mAb) tumor sensitization to chemotherapeutic agents, activation of CBE11 inhibited tumor growth in xenograft models and antitumor immunity, and disruption of tumor-associated micro- potentiated tumor responses to chemotherapeutic agents.
    [Show full text]
  • Commentary Mechanisms of Tumor Necrosis Factor Α Action On
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 9449–9451, August 1999 Commentary Mechanisms of tumor necrosis factor ␣ action on neurodegeneration: Interaction with insulin-like growth factor-1 Sarah A. Loddick and Nancy J. Rothwell* School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom The role of cytokines and growth factors in diverse forms of cause cell death when infused into a normal rodent brain, there neurodegeneration is now widely recognized. Several proin- is considerable evidence that TNF␣ mediates neuronal death flammatory cytokines, notably tumor necrosis factor (TNF) ␣ in an injured brain (e.g., ref. 9). Administration of exogenous and IL-1, have been shown to mediate diverse forms of TNF␣ markedly exacerbates ischemic injury in vivo (7) and, experimental neurodegeneration (1, 2), although in several most importantly, acute inhibition of TNF␣ action, by admin- cases both neurotoxic and neuroprotective actions have been istration of TNF soluble receptor (which prevents its action) (7, reported. Similarly numerous growth factors, including insu- 11) or a neutralizing antibody to TNF␣ (e.g., refs. 7 and 12) lin-like growth factor (IGF), fibroblast growth factor, trans- markedly attenuates ischemic brain damage in rat and mouse. forming growth factor ␤, ciliary neurotrophic factor, vascular In contrast, studies in mice lacking TNF␣ receptor suggest endothelial growth factor, glia-derived neurotrophic factor, that TNF␣ may also have neuroprotective actions, mediated by brain-derived neurotrophic factor, nerve growth factor, and the p55 receptor (13, 14). Ischemic and excitotoxic injury is several neurotrophins have neuroprotective and͞or neurotro- greater in animals that lack either the p55 receptor or both phic actions in vivo and in vitro (e.g., refs.
    [Show full text]
  • Eda-Activated Relb Recruits an SWI/SNF (BAF) Chromatin-Remodeling Complex and Initiates Gene Transcription in Skin Appendage Formation
    Eda-activated RelB recruits an SWI/SNF (BAF) chromatin-remodeling complex and initiates gene transcription in skin appendage formation Jian Simaa,1,2, Zhijiang Yana,1, Yaohui Chena, Elin Lehrmanna, Yongqing Zhanga, Ramaiah Nagarajaa, Weidong Wanga, Zhong Wangb, and David Schlessingera,2 aLaboratory of Genetics and Genomics, National Institute on Aging/NIH-Intramural Research Program, Baltimore, MD 21224; and bDepartment of Cardiac Surgery, Cardiovascular Research Center, University of Michigan, Ann Arbor, MI 48109 Edited by Elaine Fuchs, The Rockefeller University, New York, NY, and approved June 28, 2018 (received for review January 23, 2018) Ectodysplasin A (Eda) signaling activates NF-κB during skin ap- during organ development induce distinct BAF complexes to pendage formation, but how Eda controls specific gene transcrip- modulate gene expression. tion remains unclear. Here, we find that Eda triggers the formation Here, we report that skin-specific Eda signaling triggers the for- of an NF-κB–associated SWI/SNF (BAF) complex in which p50/RelB re- mation of a large BAF-containing complex that includes a BAF cruits a linker protein, Tfg, that interacts with BAF45d in the BAF com- complex, an NF-κB dimer of p50/RelB, and a specific linker pro- plex. We further reveal that Tfg is initially induced by Eda-mediated tein, Tfg (TRK-fusion gene). Thus, Eda/NF-κB signaling operates RelB activation and then bridges RelB and BAF for subsequent gene through a BAF complex to regulate specific gene expression in regulation. The BAF component BAF250a is particularly up-regulated in organ development, which may exemplify a more general paradigm skin appendages, and epidermal knockout of BAF250a impairs skin for gene-specific regulation in many other systems.
    [Show full text]
  • Expression Il2 Differentiation by Promoting TNFR2 Impairs Th17
    Transmembrane TNF−TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression Patrick G. Miller, Michael B. Bonn and Susan C. McKarns This information is current as J Immunol 2015; 195:2633-2647; Prepublished online 12 of October 3, 2021. August 2015; doi: 10.4049/jimmunol.1500286 http://www.jimmunol.org/content/195/6/2633 Downloaded from References This article cites 76 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/195/6/2633.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 3, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transmembrane TNF–TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression Patrick G. Miller,* Michael B. Bonn,* and Susan C. McKarns*,† The double-edged sword nature by which IL-2 regulates autoimmunity and the unpredictable outcomes of anti-TNF therapy in autoimmunity highlight the importance for understanding how TNF regulates IL-2.
    [Show full text]